Recent research suggests that LY-294002 is a potent and selective PI3K inhibitor that increases the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF-1α pathway (Xu et al., 2021). This evidence concerns the gene AKT1 and liver cancer.